Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial

Hamuryudan, VEDAT; Mat, C; Saip, SABAHATTİN; Ozyazgan, Yılmaz; Siva, AKSEL; Yurdakul, Sebahattin; Zwingenberger, K; Yazici, Hasan

doi:10.7326/0003-4819-128-6-199803150-00004

Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial

Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., ...Daha Fazla

ANNALS OF INTERNAL MEDICINE, cilt.128, sa.6, ss.443-451, 1998 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 128 Sayı: 6
Basım Tarihi: 1998
Doi Numarası: 10.7326/0003-4819-128-6-199803150-00004
Dergi Adı: ANNALS OF INTERNAL MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.443-451
Anahtar Kelimeler: thalidomide, Behcet's syndrome, oral ulcer, dose-response relationship, drug, genital diseases, male, BRITISH PATIENTS, DISEASE, NEUROPATHY, RECURRENT, TURKISH
İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Background: Recurrent oral and genital ulcers are the most frequent problem in the management of the Behcet syndrome. Uncontrolled experience suggests that thalidomide may help prevent recurrences of these ulcers.